Welcome to our dedicated page for Ascendis Pharma SEC filings (Ticker: ASND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ascendis Pharma A/S filings document foreign private issuer disclosures on Form 6-K, including operating and financial results, clinical and regulatory updates, capital-structure actions and security-structure changes. Recent reports cover TransCon CNP and TransCon hGH data in achondroplasia, the ordinary-share Nasdaq listing that replaced the ADS program, and the exchange of outstanding ADSs into ordinary shares.
The filing record also discloses convertible senior note redemption terms, warrant grants under the company's Articles of Association, registration-statement incorporation by reference, and equity-compensation capacity. Financial disclosures include IFRS reporting items, fair-value and derivative measurements, share capital accounts, treasury shares, and product-related revenue and royalty arrangements.
Ascendis Pharma A/S director Jan Moller Mikkelsen filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. He directly holds 384,933 ordinary shares and indirectly holds 68,470 ordinary shares through Cadenza Partners.
The filing lists several fully vested, currently exercisable warrant series over ordinary shares with exercise prices ranging from 37.18 to 176.28 and expirations from December 2027 through December 2031. It also discloses three restricted stock unit awards over ordinary shares (delivered as ADSs) covering 15,825, 23,834 and 28,945 underlying shares, which vest beginning on March 1, 2027.
Ascendis Pharma A/S officer Jensen Flemming Steen filed an initial ownership report showing a mix of ordinary shares, warrants, and restricted stock units tied to the company’s equity. He holds 19,460 ordinary shares directly, including American Depositary Shares where each ADS represents one ordinary share.
His derivative position includes fully vested, currently exercisable warrants over 20,000, 27,000, 22,755 and 14,504 ordinary shares at exercise prices of 62.1700, 108.0000, 176.2800 and 139.6500 respectively. He also holds restricted stock units covering 4,246, 3,197 and 9,552 ordinary shares, each RSU representing a contingent right to receive one ADS. These RSUs vest over time beginning on March 1, 2027 and have no expiration date.
Ascendis Pharma A/S director Cha Albert has filed an initial ownership report showing a mix of ordinary shares, warrants and restricted stock units. The filing lists 3,730 ordinary shares held directly. It also discloses fully vested warrants over 542 ordinary shares at an exercise price of $62.1700 expiring on December 11, 2028, 7,500 ordinary shares at $108.0000 expiring on December 10, 2029, 6,420 ordinary shares at $176.2800 expiring on December 10, 2030, and 3,053 ordinary shares at $139.6500 expiring on December 9, 2031. In addition, Cha holds restricted stock units covering 1,374, 2,070 and 1,930 ordinary shares, each representing a right to receive one American Depositary Share, with vesting beginning on March 1, 2027.
Ascendis Pharma A/S executive Shu Aimee, EVP & Chief Medical Officer, filed an initial Form 3 reporting equity holdings in the company. The filing lists direct holdings of restricted stock units (RSUs) convertible into 6,532, 3,197, and 9,552 ordinary shares, plus no directly held ordinary shares. Each RSU represents a right to receive one American Depositary Share, and each ADS represents one ordinary share. The RSUs vest beginning on March 1, 2027, with some grants vesting fully on that date and others in two or three equal annual installments starting then.
Ascendis Pharma A/S reported positive Week 52 topline results from New InsiGHTS, a Phase 2 clinical trial in the U.S. The study compared once-weekly TransCon hGH (lonapegsomatropin) with daily somatropin in prepubertal children with Turner syndrome.
The trial enrolled and dosed 49 children aged 1 to 10 years, who received either the weekly or daily growth hormone regimen. Doses for both treatments were then individualized based on IGF-1 levels to tailor therapy for each child.
Ascendis Pharma A/S reports new 104-week data from its pivotal ApproaCH Trial in children with achondroplasia treated once weekly with TransCon CNP (navepegritide). The data show children maintained consistent improvements in growth through Week 104, with further improvement in body proportionality during the second treatment year.
The randomized, double-blind, placebo-controlled trial enrolled 84 children aged 2–11 years, with a 52-week placebo-controlled phase followed by an open-label extension to Week 104. TransCon CNP, a prodrug of C-type natriuretic peptide, is designed for continuous CNP exposure to counter overactive FGFR3 signaling.
In February 2026, TransCon CNP was approved by the U.S. FDA under the trade name YUVIWEL to increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses. A Marketing Authorization Application for YUVIWEL is under review by the European Medicines Agency, with a regulatory decision anticipated in the fourth quarter of 2026.
Ascendis Pharma A/S reports that its board granted 22,480 warrants to certain employees under its Articles of Association. Each warrant allows the holder to buy one ordinary share at an exercise price of US $240.52, matching the ADS closing price on the grant date.
Twenty-five percent of the warrants vest one year after the grant, with the remaining 75% vesting monthly over the following three years, subject to continued service and possible earlier vesting on certain exit events. After this grant, warrants to subscribe for an additional 1,644,153 shares remain available for future grants.
Ascendis Pharma A/S intends to sell 10,000 American Depositary Shares (ADS) by 03/05/2026. The filing lists the sale method as a warrant exercise for $2,400,000.00 and indicates trading on Nasdaq. The transaction type is listed as cash.